# Superior vena cava obstruction in cancer: recognition, imaging, stenting and treatment of the cause

Source: https://onco.cc/protocols/svc-obstruction/  
OnCo record `svc-obstruction` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A cancer in the chest, most often lung cancer or lymphoma, can squeeze the large vein that brings blood back from the head and arms. The face, neck and arms swell, and breathing can become difficult: this needs urgent hospital assessment the same day. A CT scan confirms it; a small metal tube (stent) in the vein can relieve symptoms within days, and chemotherapy or radiotherapy treats the cancer.

## Summary

Malignant SVCO is caused by external compression, thrombosis or direct invasion of the superior vena cava; lung cancer accounts for 65 to 80%, lymphoma for 2 to 10% (Scottish Palliative Care Guidelines). It may be the first presentation of the cancer. Symptoms are those of venous hypertension: breathlessness, headache worse on stooping, swelling of the face, neck and arms, visual change and dizziness; signs include non-pulsatile distended neck veins, chest wall collaterals and, late, stridor and papilloedema. A chest X-ray and CT confirm it; CT venography and MR venography are the primary imaging studies (Sen 2026).

NICE NG122 (2005 recommendations, still current) offers chemotherapy and radiotherapy according to stage and performance status, and considers a stent for immediate relief of severe symptoms or after failure of earlier treatment. The Scottish guideline adds loosening clothing and supporting the arms, urgent discussion with oncology, radiotherapy or respiratory medicine, chemotherapy and radiotherapy for small-cell lung cancer, consideration of stenting, thrombectomy, thrombolysis and anticoagulation, and dexamethasone 16 mg then 8 mg twice daily, noting that steroids may help despite the absence of evidence. A systematic review (Rowell and Gleeson 2002) found chemotherapy and/or radiotherapy relieved SVCO in 77% with small-cell and 60% with non-small-cell lung cancer, and a stent in 95%, more rapidly; the effectiveness of steroids and the best timing of a stent were uncertain. A 2026 vascular review calls stenting first-line for symptomatic SVC syndrome of any cause (pooled clinical success 96.8% in 2249 patients; fatal complications 1 to 2%), and the Annals of Palliative Medicine 2024 review reserves immediate stenting for airway compromise, laryngeal oedema or cerebral oedema, after complete staging to decide whether treatment is curative or palliative.

## Fields

- Kind: Protocol
- Last checked: 2026-11-11
- Also known as: SVCO; SVC syndrome; superior vena cava syndrome; malignant SVC obstruction; SVC stent
- Tags: protocol; acute-oncology; oncological-emergency

## Connected records

- protocols: [Metastatic spinal cord compression: recognition, MSCC coordinator, MRI, dexamethasone, radiotherapy and surgery](https://onco.cc/protocols/metastatic-spinal-cord-compression-emergency/)
- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [CT (computed tomography)](https://onco.cc/technologies/ct/), [Palliative radiotherapy](https://onco.cc/technologies/palliative-radiotherapy/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/)
- institutions: [National Institute for Health and Care Excellence](https://onco.cc/institutions/nice/)
- terms: [Superior vena cava obstruction](https://onco.cc/terms/superior-vena-cava-obstruction/)

---
JSON: https://onco.cc/api/v1/entities/svc-obstruction.json